NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MGNX shares have decreased by 10.3% and is now trading at $5.82. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for MacroGenics.

MacroGenics Inc (NASDAQ:MGNX) posted its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.10. The biopharmaceutical company earned $25.19 million during the quarter, compared to analyst estimates of $10.74 million. MacroGenics had a negative net margin of 236.51% and a negative return on equity of 55.16%. View MacroGenics' earnings history.

12 Wall Street analysts have issued 1 year target prices for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $18.91 in the next twelve months. This suggests a possible upside of 224.9% from the stock's current price. View analysts' price targets for MacroGenics.

News headlines about MGNX stock have been trending extremely positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a coverage optimism score of 5.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutMacroGenics.

MacroGenics saw a decrease in short interest in February. As of February 28th, there was short interest totaling 3,670,000 shares, a decrease of 5.2% from the February 13th total of 3,870,000 shares. Based on an average daily volume of 486,000 shares, the short-interest ratio is currently 7.6 days. Approximately 8.5% of the company's shares are sold short. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Tricida (TCDA), Ligand Pharmaceuticals (LGND), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Zogenix (ZGNX), Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), Amneal Pharmaceuticals (AMRX), Akebia Therapeutics (AKBA), Enanta Pharmaceuticals (ENTA), NextCure (NXTC), Opko Health (OPK), Aimmune Therapeutics (AIMT) and Revance Therapeutics (RVNC).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), NVIDIA (NVDA), TherapeuticsMD (TXMD), Incyte (INCY), Karyopharm Therapeutics (KPTI), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (3.94%), Sofinnova Investments Inc. (2.40%), Rhenman & Partners Asset Management AB (2.17%), Pinnacle Associates Ltd. (1.75%), FMR LLC (1.70%) and Candriam Luxembourg S.C.A. (1.53%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Jefferies Group LLC, Spark Investment Management LLC, Massachusetts Financial Services Co. MA, Citigroup Inc., and New York State Common Retirement Fund. View insider buying and selling activity for MacroGenics.

MGNX stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Pinnacle Associates Ltd., Rhenman & Partners Asset Management AB, Panagora Asset Management Inc., Oxford Asset Management LLP, Geode Capital Management LLC, Principal Financial Group Inc., and Amia Capital LLP. View insider buying and selling activity for MacroGenics.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $5.82.

MacroGenics has a market capitalization of $285.94 million and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe. View additional information about MacroGenics.

The official website for MacroGenics is http://www.macquarie.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.